Baseline tumour measurements predict survival in advanced non-small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q37182213

about

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It?Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors.Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

P2860

Q36233903-B5522769-4240-4767-BAE7-D8BC0A4A54D9 Q50068855-1C579732-B14A-4935-86EA-EE52F091B931 Q50088538-1CA59BCC-33A0-4188-8C3C-ECC4D572B73A Q50736135-77CD28A8-CD30-4B39-A58A-26C5FBB80B57 Q51795514-BE0B7CDE-3DF8-44D2-B215-95124F719C80 Q53045959-367D5A73-A280-4D04-B09F-D54E1086A165 Q53060926-F8812825-0D31-47AD-ABAA-B758BBAA0221 Q58799261-0C65E42B-19E1-4EE1-9C5F-252051DFA156 Q58799565-1DFB552D-E401-43FD-996A-2E13F96D8362

P2860

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q37182213

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@en

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@nl

type

label

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@en

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@nl

prefLabel

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@en

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@nl

P1433

Q37182213-735FEA21-6EBB-4936-99ED-CF6DACCB1D0A

P1476

Q37182213-A1DE64B7-6278-4F98-BE4F-E80F8CCF40F5

P2093

Q37182213-165B627D-0860-4505-B1F0-DFC49A3D73A6

Q37182213-2689470C-BCA7-49C5-8D03-65D398EF5031

Q37182213-730D0324-349C-497F-B364-3C662B0F5DF9

Q37182213-8E3AAD73-F6A6-426C-89F7-F57906421F9F

Q37182213-C943CE0A-58B2-4E4C-9EF0-864144B22988

Q37182213-CC43A39C-092E-471D-A4B0-9FF12FBB2819

Q37182213-E3835205-24B4-4AD1-8E59-74B26D6A2DEE

P2860

Q37182213-00DD2A56-0821-4DA6-8336-AF60E52D8C47

Q37182213-014F48B0-8ABC-4B38-98DE-17C4C41ED0CB

Q37182213-0B120FA9-666B-4718-AB10-6B0FBE96A665

Q37182213-249D94AB-F539-4A3C-B9F7-69E11D041DEC

Q37182213-26A25754-E90B-48ED-AAF8-B25EDD72EBB9

Q37182213-28489998-8AFE-4B7C-A7BB-637BF5BD4738

Q37182213-41B32D31-A8B4-4EDA-8939-EFCC54FB9EA5

Q37182213-4CB6F3F8-2C95-4331-9741-2640127541A9

Q37182213-531AB51B-2DC2-4DD5-BCB8-7A5A3A8235FD

Q37182213-5C3A3C53-EFEF-4962-8DBB-8B68083D6E44

P2888

Q37182213-021A581B-DD92-4E47-8916-610C357CD4ED

P304

Q37182213-80D0C3EF-9F02-4A11-A809-CD645D3B9266

P31

Q37182213-14C533FB-A466-4217-B9DD-71D7B92E68DB

P356

Q37182213-A0E8760E-6EEC-4DCD-A32E-9602EED02F95

P407

Q37182213-BD7FF1D8-30FC-4541-B37A-81DC95AA40F0

P433

Q37182213-EB257AB6-A374-447D-9446-994F76F00EC8

P478

Q37182213-C7E50DD5-A185-472B-8359-56F1AB796B8A

P577

Q37182213-9930B4F9-0FA2-47FA-A6EC-C9F1E89E6AA3

P5875

Q37182213-DDBD470F-4343-4DEC-8BE1-A5F5AA828A93

P698

Q37182213-EE6A507B-4B2B-41D5-B6EF-4A89F7D62432

P932

Q37182213-AA1BE64C-C9A4-4CCB-9375-91E04228DB57

P356

P1433

British Journal of Cancer

P1476

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

@en

P2093

A B Sandler

http://www.w3.org/2001/XMLSchema#string

D E Gerber

http://www.w3.org/2001/XMLSchema#string

D H Ahn

http://www.w3.org/2001/XMLSchema#string

D H Johnson

http://www.w3.org/2001/XMLSchema#string

J H Schiller

http://www.w3.org/2001/XMLSchema#string

J R Brahmer

http://www.w3.org/2001/XMLSchema#string

S E Dahlberg

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Drug resistance and the solid tumor microenvironment

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.

Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003.

P2888

P304

1476-1481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.472

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255951726

http://www.w3.org/2001/XMLSchema#string

P698

23942074

http://www.w3.org/2001/XMLSchema#string

P932

3776984

http://www.w3.org/2001/XMLSchema#string